Biopharmaceutical companies looking to raise money in 2025 can expect more of the same as what they experienced in 2024, according to market observers who were in San Francisco for the recent J.P. Morgan Healthcare Conference and concurrent Biotech Showcase. That means a little more support from investors as long as big pharma continues buying smaller firms, with some enduring reluctance to invest due to ongoing macroeconomic issues and regulatory uncertainty.
Key Takeaways
- High interest rates and other macro issues continue to impact biopharma company valuations and investor interest, but specialist investors see reasons to back drug developers...
High interest rates continue to plague the financial markets, making capital more expensive for biopharma firms and causing riskier investments – like drug development – to be less attractive to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
